Key clinical point: The triple-drug combo was recently approved by the FDA as the first new treatment for Helicobacter pylori since 1997.
Major finding: The H. pylori eradication rate was 84% with rifabutin-based triple therapy and 58% with high-dose dual therapy with amoxicillin plus omeprazole.
Study details: This was a phase 3, double-blind, multicenter, active comparator–controlled randomized trial including 455 participants with H. pylori infection.
Disclosures: The presenter reported having no financial conflicts regarding the study, sponsored by RedHill Biopharma.
Graham DY. ACG 2019, Abstract 63.
This Week's Must Reads
Must Reads in Antimicrobial-resistant infections
Antibiotic Use and Hospital Onset CDI Infection, Clin Infect Dis; ePub 2019 Mar 1; Kazakova, et al